These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 16320645)

  • 1. [Prostate carcinoma. What does PSA screening bring?].
    Schultze-Seemann W
    MMW Fortschr Med; 2005 Nov; 147(45):13. PubMed ID: 16320645
    [No Abstract]   [Full Text] [Related]  

  • 2. [Early detection of prostatic carcinoma: Is PSA screening suitable?].
    Kaulen H
    Dtsch Med Wochenschr; 2003 May; 128(18):977. PubMed ID: 12755136
    [No Abstract]   [Full Text] [Related]  

  • 3. Inter-relation between measurement of serum prostatic specific antigen and transrectal ultrasound in the diagnosis of benign prostatic hyperplasia and prostatic cancer.
    Clements R; Etherington RJ; Griffiths GJ; Peeling WB; Hughes H; Penney MD
    Br J Urol; 1992 Aug; 70(2):183-7. PubMed ID: 1382795
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia].
    Maksimov VA; Kamalov AA; Karpov VK; Riaboĭ AV; Prokhorov AV
    Urologiia; 2001; (2):37-40. PubMed ID: 11490716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prostatic specific antigen (PSA).
    Alberti C
    Minerva Urol Nefrol; 1993 Jun; 45(2):83-4. PubMed ID: 7694380
    [No Abstract]   [Full Text] [Related]  

  • 6. [Present-day possibilities of prostate cancer screening in patients with benign prostatic hyperplasia before and after surgical treatment].
    Pushkar' DIu; Rasner PI; Skobelev PP
    Urologiia; 2001; (6):48-54. PubMed ID: 11785083
    [No Abstract]   [Full Text] [Related]  

  • 7. [Measurement of complexed prostatic specific antigen. A new challenge in PSA era].
    Morote Robles J
    Med Clin (Barc); 2004 Feb; 122(7):256-8. PubMed ID: 15012874
    [No Abstract]   [Full Text] [Related]  

  • 8. The use of prostate-specific antigen and free/total prostate-specific antigen in the diagnosis of localized prostate cancer.
    Partin AW; Carter HB
    Urol Clin North Am; 1996 Nov; 23(4):531-40. PubMed ID: 8948408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the clinical value of complexed PSA and total PSA in the discrimination between benign prostatic hyperplasia and prostate cancer.
    Froehner M; Hakenberg OW; Koch R; Schmidt U; Meye A; Wirth MP
    Urol Int; 2006; 76(1):27-30. PubMed ID: 16401917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples.
    Lein M; Jung K; Brux B; Knäbich A; Sinha P; Schnorr D; Loening SA
    J Urol; 1999 Aug; 162(2):502-3. PubMed ID: 10411077
    [No Abstract]   [Full Text] [Related]  

  • 11. [Circulating prostatic-specific antigen in benign hypertrophy and localized prostate cancer: can PSA be considered a screening examination for localized cancer?].
    Perrin P; Francois O; Maquet JH; Bringeon G; Duteil P; Devonec M
    Prog Urol; 1991 Jun; 1(3):419-31. PubMed ID: 1726943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer and prostate specific antigen. A Jamaican perspective.
    Douglas LL
    West Indian Med J; 1999 Jun; 48(2):47-9. PubMed ID: 10492600
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
    Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
    Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Usefulness of PSA density (PSAD) in the differential diagnosis between prostatic adenocarcinoma and benign ++ prostatic hypertrophy].
    Tiranti D; Annoscia S; Montefiore F; Boccafoschi C
    Arch Ital Urol Androl; 1994 Sep; 66(4 Suppl):59-63. PubMed ID: 7534168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
    Bratt O; Björk T
    Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
    [No Abstract]   [Full Text] [Related]  

  • 17. Free PSA as a percentage of the total: where do we go from here?
    Moore RA
    Clin Chem; 1997 Sep; 43(9):1561-2. PubMed ID: 9299933
    [No Abstract]   [Full Text] [Related]  

  • 18. The PSA revisited: potentials and pitfalls.
    Harv Mens Health Watch; 1999 Jun; 3(11):1-5. PubMed ID: 10233802
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of prostate-specific antigen density in predicting prostate cancer when serum prostate-specific antigen levels are less than 10 ng/ml.
    Akdas A; Tarcan T; Türkeri L; Cevik I; Biren T; Ilker Y
    Eur Urol; 1996; 29(2):189-92. PubMed ID: 8647145
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimum prostate-specific antigen (PSA) level diagnostic of prostate cancer.
    Yesner R; Kelly LJ; Chan YK
    Conn Med; 1996 Jul; 60(7):399-404. PubMed ID: 8758658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.